enGene Therapeutics (ENGN) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tenaya Therapeutics (TNYA) has outperformed enGene Therapeutics (ENGN) over the past year, losing 69.9% versus a loss of 75.1%. Tenaya Therapeutics is the larger company by market cap ($122.0 million vs $119.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | TNYA |
|---|---|---|
| Share price | $1.78 | $0.5442 |
| Market cap | $119.29M | $122.03M |
| 1-day change | +2.01% | +2.02% |
| YTD return | -80.68% | -25.08% |
| 1-year return | -75.11% | -69.86% |
| 5-year return | — | -97.41% |
| EPS (TTM) | $-2.07 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.25 | $2.35 |
| 52-week low | $1.40 | $0.5211 |
| Distance from 52-week high | -85.47% | -76.84% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +488.02% |
| Average volume | 746.58K | 2.26M |
| Shares outstanding | 67.02M | 224.23M |
| Employees | — | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
ENGN vs TNYA FAQ
Which is bigger, enGene Therapeutics or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $122.03M compared with $119.29M for enGene Therapeutics (ENGN).
Which stock has performed better over the past year, ENGN or TNYA?
TNYA returned -69.86% over the past 12 months, compared with -75.11% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.